Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease

Neuroscience

Volumn 169, Issue 2, 2010, Pages 781-786

  Amtul, Z ^a,b   Wang, L ^a   Westaway, D ^c   Rozmahel, R F ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

A ; Alzheimer's disease; APP; BACE; Estradiol; TTR

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; ESTRADIOL; INSULINASE; PREALBUMIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HORMONAL THERAPY; MENOPAUSE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; ESTRADIOL; ESTROGENS; FEMALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUTATION; NEUROPROTECTIVE AGENTS; PLAQUE, AMYLOID;

EID: 77954623481     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.05.031     Document Type: Article

References (48)

1. Amtul Z., Lewis P.A., Piper S., Crook R., Baker M., Findlay K., Singleton A., Hogg M., Younkin L., Younkin S.G., Hardy J., Hutton M., Boeve B.F., Tang-Wai D., Golde T.E. A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch. Neurobiol Dis 2002, 9:269-273.
2. Annaert W., De Strooper B. A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol 2002, 18:25-51.
3. Asthana S., Baker L.D., Craft S., Stanczyk F.Z., Veith R.C., Raskind M.A., Plymate S.R. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001, 57:605-612.
4. Asthana S., Raffaele K.C., Greig N.H., Schapiro M.B., Blackman M.R., Soncrant T.T. Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 1999, 13:102-108.
5. Baldereschi M., Di Carlo A., Lepore V., Bracco L., Maggi S., Grigoletto F., Scarlato G., Amaducci L. Estrogen-replacement therapy and Alzheimer's disease in the Italian longitudinal study on aging. Neurology 1998, 50:996-1002.
6. Brijbassi S., Amtul Z., Newbigging S., Westaway D., St George-Hyslop P., Rozmahel R.F. Excess of nicastrin in brain results in heterozygosity having no effect on endogenous APP processing and amyloid peptide levels in vivo. Neurobiol Dis 2007, 25:291-296.
7. Buxbaum J.N., Ye Z., Reixach N., Friske L., Levy C., Das P., Golde T., Masliah E., Roberts A.R., Bartfai T. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A 2008, 105:2681-2686.
8. Chang D., Kwan J., Timiras P.S. Estrogens influence growth, maturation, and amyloid beta-peptide production in neuroblastoma cells and in a beta-APP transfected kidney 293 cell line. Adv Exp Med Biol 1997, 429:261-271.
9. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001, 276:21562-21570.
10. Goncalves I., Alves C.H., Quintela T., Baltazar G., Socorro S., Saraiva M.J., Abreu R., Santos C.R. Transthyretin is up-regulated by sex hormones in mice liver. Mol Cell Biochem 2008, 317:137-142.
11. Goodman Y., Bruce A.J., Cheng B., Mattson M.P. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem 1996, 66:1836-1844.
12. Green P.S., Gridley K.E., Simpkins J.W. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett 1996, 218:165-168.
13. Greenfield J.P., Leung L.W., Cai D., Kaasik K., Gross R.S., Rodriguez-Boulan E., Greengard P., Xu H. Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis. J Biol Chem 2002, 277:12128-12136.
14. Hattori C., Asai M., Oma Y., Kino Y., Sasagawa N., Saido T.C., Maruyama K., Ishiura S. BACE1 interacts with nicastrin. Biochem Biophys Res Commun 2002, 293:1228-1232.
15. Henderson V.W., Espeland M.A., Hogan P.E., Rapp S.R., Stefanick M.L., Wactawski-Wende J., Johnson K.C., Wassertheil-Smoller S., Freeman R., Curb D. Prior use of hormone therapy and incident Alzheimer's disease in the Women's Health Initiative Memory Study. Neurology 2007, 68(Suppl 1):A205.
16. Jaffe A.B., Toran-Allerand C.D., Greengard P., Gandy S.E. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem 1994, 269:13065-13068.
17. Li T., Ma G., Cai H., Price D.L., Wong P.C. Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals. J Neurosci 2003, 23:3272-3277.
18. Maki P.M. Hormone therapy and cognitive function: is there a critical period for benefit?. Neuroscience 2006, 138:1027-1030.
19. Manthey D., Heck S., Engert S., Behl C. Estrogen induces a rapid secretion of amyloid beta precursor protein via the mitogen-activated protein kinase pathway. Eur J Biochem 2001, 268:4285-4291.
20. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
21. Miller D.L., Papayannopoulos I.A., Styles J., Bobin S.A., Lin Y.Y., Biemann K., Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 1993, 301:41-52.
22. Mulnard R.A., Cotman C.W., Kawas C., van Dyck C.H., Sano M., Doody R., Koss E., Pfeiffer E., Jin S., Gamst A., Grundman M., Thomas R., Thal L.J. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000, 283:1007-1015.
23. Ohta H. [Role of estrogen and selective estrogen receptor modulators in anti-aging]. Clin Calcium 2008, 18:986-994.
24. O'Regan R.M., Cisneros A., England G.M., MacGregor J.I., Muenzner H.D., Assikis V.J., Bilimoria M.M., Piette M., Dragan Y.P., Pitot H.C., Chatterton R., Jordan V.C. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 1998, 90:1552-1558.
25. Paganini-Hill A., Henderson V.W. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996, 156:2213-2217.
26. Peluso J.J. Structure and function of the mammalian ovary 1996, CRC Press, Boca Raton, FL. 2nd ed.
27. Pike C.J. Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer's disease. J Neurochem 1999, 72:1552-1563.
28. Quintela T., Goncalves I., Baltazar G., Alves C.H., Saraiva M.J., Santos C.R. 17beta-estradiol induces transthyretin expression in murine choroid plexus via an oestrogen receptor dependent pathway. Cell Mol Neurobiol 2009, 29:475-483.
29. Roth R.A., Mesirow M.L., Yokono K., Baba S. Degradation of insulin-like growth factors I and II by a human insulin degrading enzyme. Endocr Res 1984, 10:101-112.
30. Savonenko A.V., Markowska A.L. The cognitive effects of ovariectomy and estrogen replacement are modulated by aging. Neuroscience 2003, 119:821-830.
31. Schafer S., Wirths O., Multhaup G., Bayer T.A. Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease. J Neural Transm 2007, 114:387-394.
32. Selkoe D.J., Yamazaki T., Citron M., Podlisny M.B., Koo E.H., Teplow D.B., Haass C. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci 1996, 777:57-64.
33. Shah S., Lee S.F., Tabuchi K., Hao Y.H., Yu C., LaPlant Q., Ball H., Dann C.E., Sudhof T., Yu G. Nicastrin functions as a gamma-secretase-substrate receptor. Cell 2005, 122:435-447.
34. Singh M., Sumien N., Kyser C., Simpkins J.W. Estrogens and progesterone as neuroprotectants: what animal models teach us. Front Biosci 2008, 13:1083-1089.
35. Slooter A.J., Bronzova J., Witteman J.C., Van Broeckhoven C., Hofman A., van Duijn C.M. Estrogen use and early onset Alzheimer's disease: a population-based study. J Neurol Neurosurg Psychiatry 1999, 67:779-781.
36. St George-Hyslop P.H. Molecular genetics of Alzheimer's disease. Biol Psychiatry 2000, 47:183-199.
37. Stein T.D., Anders N.J., DeCarli C., Chan S.L., Mattson M.P., Johnson J.A. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 2004, 24:7707-7717.
38. Steiner H. Uncovering gamma-secretase. Curr Alzheimer Res 2004, 1:175-181.
39. Tang M.X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H., Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996, 348:429-432.
40. Tang Y.P., Haslam S.Z., Conrad S.E., Sisk C.L. Estrogen increases brain expression of the mRNA encoding transthyretin, an amyloid beta scavenger protein. J Alzheimers Dis 2004, 6:413-420. discussion:443-419.
41. Udrisar D.P., Wanderley M.I., Porto R.C., Cardoso C.L., Barbosa M.C., Camberos M.C., Cresto J.C. Androgen- and estrogen-dependent regulation of insulin-degrading enzyme in subcellular fractions of rat prostate and uterus. Exp Biol Med (Maywood) 2005, 230:479-486.
42. Wang J., Ho L., Zhao Z., Seror I., Humala N., Dickstein D.L., Thiyagarajan M., Percival S.S., Talcott S.T., Pasinetti G.M. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J 2006, 20:2313-2320.
43. Waring S.C., Rocca W.A., Petersen R.C., O'Brien P.C., Tangalos E.G., Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999, 52:965-970.
44. Wilson M.E., Dubal D.B., Wise P.M. Estradiol protects against injury-induced cell death in cortical explant cultures: a role for estrogen receptors. Brain Res 2000, 873:235-242.
45. Xu H., Gouras G.K., Greenfield J.P., Vincent B., Naslund J., Mazzarelli L., Fried G., Jovanovic J.N., Seeger M., Relkin N.R., Liao F., Checler F., Buxbaum J.D., Chait B.T., Thinakaran G., Sisodia S.S., Wang R., Greengard P., Gandy S. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 1998, 4:447-451.
46. Yao K., Lee E.S., Bentrem D.J., England G., Schafer J.I., O'Regan R.M., Jordan V.C. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000, 6:2028-2036.
47. Yue X., Lu M., Lancaster T., Cao P., Honda S., Staufenbiel M., Harada N., Zhong Z., Shen Y., Li R. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci U S A 2005, 102:19198-19203.
48. Zhao J., Fu Y., Yasvoina M., Shao P., Hitt B., O'Connor T., Logan S., Maus E., Citron M., Berry R., Binder L., Vassar R. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci 2007, 27:3639-3649.